Eileen O'Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in patients with pancreatic cancer.

According to O'Reilly, there is compelling science and biology behind using immunotherapy combinations in pancreatic cancer, since single-agent checkpoint inhibitors are insufficient.

In pancreatic cancer, the most promising combination is immunotherapy with a cytotoxic backbone, says O'Reilly. The disease needs to be under control for immunotherapy to work, which is why this combination has become a focus for this patient population.

Eileen O'Reilly

Articles

Dr. O'Reilly on Immunotherapy in Pancreatic Cancer